Enfermedades priónicas: historia, diversidad e importancia socioeconómica como paradigma de las Enfermedades Raras

Jorge M. Charco; Tomás Barrio; Hasier Eraña

doi:10.12795/araucaria.2021.i46.21

Autores/as

Jorge M. Charco Centro de investigación cooperativa en biociencias (CIC bioGUNE). ATLAS Molecular Pharma S
Tomás Barrio Centro de investigación cooperativa en biociencias (CIC bioGUNE). ATLAS Molecular Pharma S.L.
Hasier Eraña Centro de investigación cooperativa en biociencias (CIC bioGUNE). ATLAS Molecular Pharma S.L.

DOI:

https://doi.org/10.12795/araucaria.2021.i46.21

Palabras clave:

priones, enfermedades raras, enfermedades priónicas

Resumen

Las enfermedades raras son aquellas patologías que afectan a una proporción muy reducida de la población (menos de 50 casos por cada 100 000 personas). Por esta razón, la investigación sobre sus causas y mecanismos, algo imprescindible para dar con una forma de tratarlas o prevenirlas, es insuficiente. Por ello, los pacientes denuncien la falta de cobertura del sistema sanitario y la discriminación social que supone padecer una de estas patologías. Entre las enfermedades raras, se encuentran las denominadas enfermedades priónicas o encefalopatías espongiformes transmisibles. A pesar de ser relativamente conocidas gracias a la crisis sanitaria que supuso el “mal de las vacas locas” a finales del siglo pasado, se conoce todavía relativamente poco sobre estas patologías que afectan tanto a animales como a humanos. En este monográfico se pretende dar a conocer la fascinante historia y la diversidad de las enfermedades priónicas, que sacudieron los cimientos de la biología conocida hasta los años 80 al poner en escena a un nuevo y desconcertante tipo de agente infeccioso: los priones.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

Alper, T. (1972). The nature of the scrapie agent. Journal of Clinical Pathology.Supplement (Royal College of Pathologists), 6, 154-155.

Benestad, S. L., et al. (2016). First case of chronic wasting disease in europe in a norwegian free-ranging reindeer. Veterinary Research, 47(1), 88-016-0375-4. doi:10.1186/s13567-016-0375-4

Bonda, D. J., et al. (2016). Human prion diseases: Surgical lessons learned from iatrogenic prion transmission. Neurosurgical Focus, 41(1), E10. doi:10.3171/2016.5.FOCUS15126

Brown, P. (2009). Reflections on a half-century in the field of transmissible spongiform encephalopathy. Folia Neuropathologica, 47(2), 95-103. doi:12704

Brown, P., et al. (2012). Iatrogenic creutzfeldt-jakob disease, final assessment. Emerging Infectious Diseases, 18(6), 901-907. doi:10.3201/eid1806.120116

Budka, H., et al. (1995). Neuropathological diagnostic criteria for creutzfeldt-jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathology, 5(4), 459-466.

Bueler, H., et al. (1993). Mice devoid of PrP are resistant to scrapie. Cell, 73(7), 1339-1347. doi:0092-8674(93)90360-3

Coca, J. R., et al. (2019). Análisis cualitativo del impacto social y familiar de las encefalopatías espongiformes transmisibles humanas. Revista De Neurología, 69, 242-248. doi:10.33588/ rn.6906.2019122

Cohen, F. E., & Prusiner, S. B. (1998). Pathologic conformations of prion proteins. Annual Review of Biochemistry, 67, 793-819. doi:10.1146/annurev.biochem.67.1.793

Collinge, J., et al. (1996). Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature, 383(6602), 685-690. doi:10.1038/383685a0

Creutzfeldt, H. (1920). Über eine eigenartige herdförmige erkrankung des zentralnervensystems. Z Gesamte Neurol Psychiatr, 57, 1-19.

Chandler, R. L. (1961). Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet, 1(7191), 1378-1379. doi:10.1016/s0140-6736(61)92008-6

Chesebro, B., et al. (1985). Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature, 315(6017), 331-333. doi:10.1038/315331a0

Duffy, P., et al. (1974). Letter: Possible person-to-person transmission of creutzfeldt-jakob disease. The New England Journal of Medicine, 290(12), 692-693.

Duque Velasquez, C., et al. (2015). Deer prion proteins modulate the emergence and adaptation of chronic wasting disease strains. Journal of Virology, 89(24), 12362-12373. doi:10.1128/JVI.02010-15

Erana, H., et al. (2017). Prion-like disorders and transmissible spongiform encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins. Biochemical and Biophysical Research Communications, 483(4), 1125-1136. doi:S0006-291X(16)31430-9

European Commission. (n.d.). Rare diseases. retrieved 2020, nov 7. Https://Ec.Europa.Eu/Health/Non_communicable_diseases/Rare_diseases_en,

FEDER. (n.d.). Federación española de enfermedades raras. Https://Enfermedades-Raras.Org/,

Gajdusek, D. C. (1967). Slow-virus infections of the nervous system. The New England Journal of Medicine, 276(7), 392-400. doi:10.1056/NEJM196702162760708

Gajdusek, D. C., et al. (1967). Transmission and passage of experimenal "kuru" to chimpanzees. Science (New York, N.Y.), 155(3759), 212-214.

Gajdusek, D. C., et al. (1966). Experimental transmission of a kuru-like syndrome to chimpanzees. Nature, 209(5025), 794-796.

Gambetti, P., et al. (2008). A novel human disease with abnormal prion protein sensitive to protease. Annals of Neurology, 63(6), 697-708. doi:10.1002/ana.21420

Gambetti, P., et al. (2003). Sporadic and familial CJD: Classification and characterisation. British Medical Bulletin, 66, 213-239. doi:10.1093/bmb/66.1.213

Gibbs, C. J.,Jr, et al. (1968). Creutzfeldt-jakob disease (spongiform encephalopathy): Transmission to the chimpanzee. Science, 161(3839), 388-389. doi:10.1126/science.161.3839.388

Glatzel, M., et al. (2005). Human prion diseases: Molecular and clinical aspects. Archives of Neurology, 62(4), 545-552. doi:62/4/545

Hadlow, W. J. (2008). Kuru likened to scrapie: The story remembered. Philosophical Transactions of the Royal Society of London.Series B, Biological Scis, 363(1510), 3644. doi:10.1098/rstb.2008.4013

Hill, A. F., et al. (1997). The same prion strain causes vCJD and BSE. Nature, 389(6650), 448-50, 526. doi:10.1038/38925

Hill, A. F., et al. (2003). Molecular classification of sporadic creutzfeldt-jakob disease. Brain, 126(Pt 6), 1333-1346.

Houston, F., & Andreoletti, O. (2019). Animal prion diseases: The risks to human health. Brain Pathology (Zurich, Switzerland), 29(2), 248-262. doi:10.1111/bpa.12696

Huor, A., et al. (2019). The emergence of classical BSE from atypical/Nor98 scrapie. Proceedings of the National Academy of Sciences of the United States of America, doi:201915737

Jakob, A. (1921). Über eigenartige erkrankungen des zentralnervensystems mit bemerkenswertem anatomischem. befunde. (spastische pseudosklerose- encephalomyelopathie mit disseminierten degenerationsherden). Z Gesamte Neurol Psychiatr, 64, 147-228.

Johnson, R. T., & Gibbs, C. J.,Jr. (1998). Creutzfeldt-jakob disease and related transmissible spongiform encephalopathies. The New England Journal of Medicine, 339(27), 1994-2004. doi:10.1056/NEJM199812313392707

Klatzo, I., et al. (1959). Pathology of kuru. Laboratory Investigation; a Journal of Technical Methods and Pathology, 8(4), 799-847.

Konold, T., et al. (2004). Clinical findings in 78 suspected cases of bovine spongiform encephalopathy in great britain. The Veterinary Record, 155(21), 659-666. doi:10.1136/vr.155.21.659

Kovacs, G. G., et al. (2005). Genetic prion disease: The EUROCJD experience. Human Genetics, 118(2), 166-174. doi:10.1007/s00439-005-0020-1

Kretzschmar, H. A., et al. (1995). Codon 178 mutation of the human prion protein gene in a german family (backer family): Sequencing data from 72-year-old celloidin-embedded brain tissue. Acta Neuropathologica, 89(1), 96-98.

Latarjet, R., et al. (1970). Inactivation of the scrapie agent by near monochromatic ultraviolet light. Nature, 227(5265), 1341-1343. doi:10.1038/2271341a0

Liberski, P. P. (2012). Historical overview of prion diseases: A view from afar. Folia Neuropathologica, 50(1), 1-12. doi:18385

Liberski, P. P., et al. (2019). Kuru, the first human prion disease. Viruses, 11(3), 10.3390/v11030232. doi:E232

Linsell, L., et al. (2004). A case-control study of sporadic creutzfeldt-jakob disease in the united kingdom: Analysis of clustering. Neurology, 63(11), 2077-2083. doi:63/11/2077

Mathiason, C. K. (2017). Scrapie, CWD, and transmissible mink encephalopathy. Progress in Molecular Biology and Translational Science, 150, 267-292. doi:S1877-1173(17)30119-9

Minikel, E. V., et al. (2016). Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 8(322), doi:10.1126/scitranslmed.aad5169

Nguengang Wakap, S., et al. (2020). Estimating cumulative point prevalence of rare diseases: Analysis of the orphanet database. European Journal of Human Genetics : EJHG, 28(2), 165-173. doi:10.1038/s41431-019-0508-0

Notari, S., et al. (2014). Transmission characteristics of variably protease-sensitive prionopathy. Emerging Infectious Diseases, 20(12), 2006-2014. doi:10.3201/eid2012.140548

Pattison, I. H., & Millson, G. C. (1961). Scrapie produced experimentally in goats with special reference to the clinical syndrome. Journal of Comparative Pathology, 71, 101-109.

Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie. Science, 216(4542), 136-144.

Prusiner, S. B. (1989). Scrapie prions. Annual Review of Microbiology, 43, 345-374. doi:10.1146/annurev.mi.43.100189.002021

Saborio, G. P., et al. (2001). Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature, 411(6839), 810-813. doi:10.1038/35081095

Song, P., et al. (2012). Rare diseases, orphan drugs, and their regulation in asia: Current status and future perspectives. Intractable & Rare Diseases Research, 1(1), 3-9. doi:10.5582/irdr.2012.v1.1.3

Takada, L. T., et al. (2017). Genetic prion disease: Experience of a rapidly progressive dementia center in the united states and a review of the literature. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 174(1), 36-69. doi:10.1002/ajmg.b.32505

Tambuyzer, E. (2010). Rare diseases, orphan drugs and their regulation: Questions and misconceptions. Nature Reviews.Drug Discovery, 9(12), 921-929. doi:10.1038/nrd3275

Tesar, A., et al. (2019). Clinical variability in P102L gerstmann-straussler-scheinker syndrome. Annals of Neurology, 86(5), 643-652. doi:10.1002/ana.25579

Thadani, V., et al. (1988). Creutzfeldt-jakob disease probably acquired from a cadaveric dura mater graft. case report. Journal of Neurosurgery, 69(5), 766-769. doi:10.3171/jns.1988.69.5.0766

Verbeke, W. (2001). Consumer reactions and economic consequences of the BSE crisis. Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie, 63(5), 483-492.

Wang, F., et al. (2010). Generating a prion with bacterially expressed recombinant prion protein. Science, 327(5969), 1132-1135. doi:10.1126/science.1183748

Wickner, R. B., et al. (2015). Yeast prions: Structure, biology, and prion-handling systems. Microbiology and Molecular Biology Reviews : MMBR, 79(1), 1-17. doi:10.1128/MMBR.00041-14

Williams, E. S. (2005). Chronic wasting disease. Veterinary Pathology, 42(5), 530-549. doi:42/5/530

Yuan, A. H., & Hochschild, A. (2017). A bacterial global regulator forms a prion. Science (New York, N.Y.), 355(6321), 198-201. doi:10.1126/science.aai7776

Zlotnik, I., & Rennie, J. C. (1965). Experimental transmission of mouse passaged scrapie to goats, sheep, rats and hamsters. Journal of Comparative Pathology, 75, 147-157.